## Richard D Press

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3402684/publications.pdf

Version: 2024-02-01

1162367 1125271 14 462 8 13 citations h-index g-index papers 14 14 14 582 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate–treated patients with CML. Blood, 2006, 107, 4250-4256.	0.6	120
2	A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response. Clinical Cancer Research, 2007, 13, 6136-6143.	3.2	115
3	Nextâ€generation sequencingâ€defined minimal residual disease before stem cell transplantation predicts acute myeloid leukemia relapse. American Journal of Hematology, 2019, 94, 902-912.	2.0	59
4	Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML. Blood, 2022, 139, 1208-1221.	0.6	48
5	The combination of NPM1, DNMT3A, and IDH1/2 mutations leads to inferior overall survival in AML. American Journal of Hematology, 2019, 94, 913-920.	2.0	31
6	Clinical Utility of Next-Generation Sequencing in Acute Myeloid Leukemia. Molecular Diagnosis and Therapy, 2020, 24, 1-13.	1.6	21
7	Discriminating a common somatic ASXL1 mutation (c.1934dup; p.G646Wfs*12) from artifact in myeloid malignancies using NGS. Leukemia, 2018, 32, 1874-1878.	3.3	18
8	A Novel Germline Variant in CSF3R Reduces N-Glycosylation and Exerts Potent Oncogenic Effects in Leukemia. Cancer Research, 2018, 78, 6762-6770.	0.4	17
9	<i>DNMT3A</i> co-mutation is required for <i>FLT3-ITD</i> as an adverse prognostic indicator in intermediate-risk cytogenetic group AML. Leukemia and Lymphoma, 2018, 59, 1938-1948.	0.6	10
10	A novel activating <i>JAK1</i> mutation in chronic eosinophilic leukemia. Blood Advances, 2021, 5, 3581-3586.	2.5	9
11	Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy. Leukemia, 2020, 34, 1684-1688.	3.3	8
12	Adult acute myeloid leukemia patients with <i>NUP98</i> rearrangement have frequent cryptic translocations and unfavorable outcome. Leukemia and Lymphoma, 2022, 63, 1907-1916.	0.6	4
13	In a multi-institutional cohort of myeloid sarcomas, <i>NFE2</i> mutation prevalence is lower than previously reported. Blood Advances, 2021, 5, 5057-5059.	2.5	2
14	BCR-ABL+ Chronic Myeloid Leukemia Arising in a Family With Inherited ANKRD26-Related Thrombocytopenia. JCO Precision Oncology, 2021, 5, 415-417.	1.5	0